Dr Kirti Hira PhD

Dr Kirti Hira is a medical writer with expertise in Pharmacology and conducting systematic literature reviews (SLR). She writes and reviews content on pharmaceutical drugs.


Dr Kirti Hira’s Highlights:


  • Associate consultant at IQVIA, India
  • PhD in Pharmacy with a focus on the Discovery of Pro-inflammatory cytokine inhibitors from bacterial strain of Pseudomonas aeruginosa at the BITS-Pilani, Hyderabad campus, India
  • Master’s in Pharmacology with a focus on the development of a new acute pancreatitis model at the NIPER, Mohali, India


Professional Experience:


Dr Kirti Hira joined IQVIA, India as soon as she completed her doctoral degree.


Dr Kirti Hira was involved in performing a systematic literature search and gap analysis to support the development of a clinical evaluation report (CER) and performance evaluation report (PER) as per EU MDR (European Medical Device Regulations) and/or EU IVDR (European In-Vitro Device Regulations).


In addition to this, she has also supported the development of a literature search strategy, reviewed and appraised the literature critically, and prepared systematic literature review (SLR) reports to identify the potential risks, safety trends, and off-label uses to ensure that the medical device safety profile is aligned with safety and marketing claims.


Dr Kirti Hira has contributed to screening, analyzing, and reviewing the published literature and clinical investigation results to evaluate the safety and performance of medical devices and pharmaceutical drugs.



  • 2014 Bachelor of Pharmacy at the Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), New Delhi, India
  • 2016 Master of Science, Pharmacology at the National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India
  • 2021 PhD in Pharmacy at BITS-Pilani, Hyderabad campus, India


The main Publications of Dr Kirti Hira are:





Book Chapter:



Conference papers:

  • Cyclo (Val-Pro) attenuates renal injury by inhibiting pro-inflammatory cytokines in mice renal ischemic model. Cytokines 2019- International Cytokines and Interferon Society, Vienna, Austria. Oct 20-23,2019.
  • Natural Diketopiperazines as TNF-α and IL-6 inhibitors. Pharmacology 2018 British Pharmacological Society, London, UK. Dec 18 – 20, 2018.
  • HDAC5/KLF2 axis regulates NLRP3-mediated renal inflammation and fibrosis associated with nephrocalcinosis-related chronic kidney disease. Nephrology Dialysis Transplantation, 35(Supplement_3), 2020
  • Tumor Necrosis Factor-alpha inhibitory activity of H.pinifolia. 24th ISCB International Conference, Manipal University, India. 11-13th Jan 2018.
  • Bioactive cyclic dipeptides of microbial origin in discovery of cytokine inhibitors. International Conference on Drug Development Technology (Dubai), Oct 16-17, 2017, 19(10) Part VIII, 888.
  •  MTT assay-guided isolation of a cytotoxic lead from Hedyotic umbellate and its mechanism of action against non-small cell lung cancer A549 cells. International Conference on Drug Development Technology (Dubai), Oct 16-17, 2017, 19(10) Part VIII, 891.
  • Screening of phyto-compounds to identify cytotoxic lead molecules against A549, MDA- MB and HT-29 cell lines and their isolation methods. 68th Indian Pharmaceutical Congress, 2016, Dec 16-18, Visakhapatnam.

You can view Dr Kirti’s work below and links to her professional profiles.


Research Gate:https://www.researchgate.net/profile/Kirti-Hira




Google Scholar:https://scholar.google.com/citations?user=hlbrGn4AAAAJ&hl=en